<a href="https://laohu8.com/S/CDNA">CareDx</a> Reports Q3 Revenue of $100.1 Million and Net Income of $1.7 Million
CareDx Inc. reported third quarter 2025 revenue of $100.1 million, a 21% increase year-over-year. Testing services revenue was $72.2 million, up 19%, with testing services volume growing 13% to 50,300. GAAP net income reached $1.7 million, compared to a net loss of $10.6 million in the same period of 2024. Adjusted EBITDA was $15.3 million, rising from $6.9 million year-over-year. Non-GAAP net income was $14.9 million, with diluted non-GAAP net income per share at $0.28. As of September 30, 2025, the company held $194.2 million in cash, cash equivalents, and marketable securities, with no debt outstanding. Full year 2025 revenue is now expected to be $372 million to $376 million, and adjusted EBITDA is forecasted between $35 million and $39 million. Recent business developments include the appointment of Suresh Gunasekaran to the Board of Directors and Jeff Teuteberg, MD, as Chief Medical Officer, completion of the first Epic Aura implementation, launch of AlloSeq Tx11, and introduction of Score 7.0 analysis software.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104307786) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.